Invivyd, Inc.

IVVD

Healthcare Biotechnology

Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024.

Revenue
+21.2%
EPS
−16.7%
Free cash flow
−226.9%

Quarter to June 2026, against a year earlier

0.56 0.03 −5.08%
Market cap
$166.0M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
−334.9%
Net debt / EBITDA
4.2×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
4.78 7.21 7.96 3.74
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(6.48) (9.65) (27.52) (22.69)
P/B ratio
1.54 1.98 1.76 2.01
EV/Sales
2.03 3.91 3.72 2.04
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(1.08) (2.75) (3.41) (1.27)
Current Ratio
5.87 6.47 7.24 2.47
Net Debt/EBITDA
3.54 4.32 18.70 8.02
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(37.93%) (23.85%) (12.96%) (42.73%)
Free Cash Flow Yield
(39.34%) (19.74%) (13.70%) (42.97%)
Free Cash Flow per Share
(0.14) (0.14) (0.09) (0.05)
Book value per Share
0.57 0.66 1.40 0.55
Free Cash Flow
(43.51) (42.44) (15.45) (8.25)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates